The list below includes links to all abstracts accepted as Oral Presentations, Posters, or for Online-Publication-Only. 

Oral Presentations and Posters are available to registered attendees only via the ASH annual meeting virtual platform, as per congress regulations.

Medical materials

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Clinical Outcomes Over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children With Severe Hemophilia A: Second Interim Analysis From the Phase 3 XTEND-ed Long-Term Extension Study

Lynn Malec, Beatrice Nolan, Anthony KC Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Real-World Clinical Outcomes for Complement inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Jens Panse , Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Barbara Czech, Brianne Kerr, Sam Williamson, Jade Garratt-Wheeldon, Yasmin Taylor, Niall Hatchell, Christopher Patriquin

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment

Naval Daver, Andrew Danquah, Didier Halimi, Jérôme Wojcik, Emmanuel Monnet

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Raajit Rampal, Michael Marrone, List Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan , Michael Vredenburg , Jia Zeng, John Mascarehnas

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Early anemia response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

John Mascarehnas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan , Michael Vredenburg , Jia Zeng, Raajit Rampal

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Association Between Hemophilia Joint Health Score and Quality of Life Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial

Christoph Königs, Doris V. Quon, Cedric Hermans, Nana Kragh, Jérôme Msihid, Emilie Gerard, Duygu Bozkaya, Linda Bystrická, Cecile LeCamus, Elena Santagostino, Annemieke Willemze, Annette von Drygalski

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents With Severe Hemophilia A: Second Interim Analysis From the Phase 3 XTEND-ed Long-Term Extension Study

Robert Klamroth, Stephanie P’ng, Sophie Susen, Davide Matino, Pratima Chowdary, Angela Weyand, Toshko Lissitchkov, Young-Shil Park, María Teresa Álvarez Román, Liqi Feng, Helena Palmborg, Jennifer Dumont , Elena Santagostino, Lara Mamikonian, Keiji Nogami

Publication
  • ASH •
  • 9 December, 2024 •
  • •

AVA 307-additonal efficacy Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune Thrombocytopenia: Open-label, Phase 3 Study

Hiroki Yamaguchi, Masaki Iino, Yutaka Imamura, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Masato Fujii , Jessica Zhang, Yoshiaki Tomiyama , Brian Jamieson

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 ADOPT Study

María Eva Mingot Castellano, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Milica Putnik, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban, Stefan Lethagen

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Real-World Paterns of Additional Factor Treatment Use Among Hemophilia A Patients on Regular Prophylaxis in the United States: Results from the PicnicHealth database

Jonathan C. Roberts, Angela Weyand, Mark Reding, Nana Kragh, Nicole Tsao, Emily Cibelli, Gillian Hanson, Duygu Bozkaya, Anne-Laure Tardy

Publication
  • ASH •
  • 9 December, 2024 •
  • •

Unmet Needs, Factor Consumption, and Healthcare Resource Use among People with Hemophilia A: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme™

Lynn Malec, Davide Matino, Kieran Wynne-Cattanach, Chris Blazos, Duygu Bozkaya, Anne-Laure Tardy, Jennifer Dumont , Sylvie Bozzi

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia A

Janice Staber, Alix Arnaud, Ion Agirrezabal, Lane Anson, Andrew Wilson, Nana Kragh, Doris V. Quon, Allison P. Wheeler

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) In Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-hoc Analyses from a Prospective Phase 4 Study

Michael Tarantino, Scott Kolodny, Michael Marrone, Brian Jamieson, Michael Vredenburg

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan , Michael Vredenburg , Jia Zeng, Raajit Rampal, John Mascarehnas

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Improvement in Serum Albumin as a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: a Retrospective Analysis of Patients Treated Across Three Clinical Trials

Francesca Palandri, Marta Sobas, Claire Harrison, Raajit Rampal, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim

Srikanth Nagalla, Moshe Y Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab as a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W. Leiding, Michael Marrone, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Publication
  • ASH •
  • 8 December, 2024 •
  • •

Results of a Prospective, Open-label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag (AVA) from Eltrombopag (ELT) or Romiplostim (ROMI)

Michael D Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Analysis of Durability of Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients with ITC

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Jessica Zhang, Brian Jamieson, Scott Kolodny

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Real-world Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate or Severe Hemophilia A: An Analysis of the Adelphi Hemophilia Disease Specific Programme™

Maissaa Janbain, Miguel Escobar, Manuel Carcao , Andrew Wilson, Jennifer Dumont , Nathan Ball, Ella Morton, Duygu Bozkaya, Anne-Laure Tardy, Sylvie Bozzi

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Anchored indirect treatment comparison finds comparable effects of pegcetacoplan and iptacopan in paroxysmal nocturnal haemoglobinuria

Régis Peffault de Latour, Jeff Szer, Koo Wilson, Piotr Wojciechowski, Zalmai Hakimi, Jameel Nazir, Barbara Czech, Austin G. Kulasekararaj

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates

David Dingli, Brian Mulherin, Peter Hillmen, Barbara Czech, Jens Panse

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience

Gloria F. Gerber, Richard J. Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Uchendu O. Uchendu, Yiwei Zhang

Publication
  • ASH •
  • 7 December, 2024 •
  • •

Reduced Iron Overload with Pegcetacoplan Treatment in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Jamile Shammo, Michael Yeh, Peter Hillmen, David J Kuter

Publication
  • ASH •
  • 7 December, 2024 •
  • •

A First Report from the COMPLETE Study on the Real-World Effectiveness of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Régis Peffault de Latour, Roochi Trikha, Carmen Gonzalez Gonzalez, Matthias Nölte, Håkan Malmström, Stefan Lethagen

Sign up for alerts